LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.13 USD | -1.52% |
|
-1.68% | 0.00% |
| 15/04 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| 15/04 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 462.9 | - | - |
| Enterprise Value (EV) 1 | 462.9 | 462.9 | 462.9 |
| P/E ratio | -6.48 x | -7.56 x | -9.51 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | 68.8 x | 8.93 x |
| EV / Revenue | - | 68.8 x | 8.93 x |
| EV / EBITDA | -6.97 x | -7.03 x | -6.3 x |
| EV / FCF | -11 x | -7.35 x | -14.9 x |
| FCF Yield | -9.07% | -13.6% | -6.7% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 25,534 | - | - |
| Reference price 2 | 18.13 | 18.13 | 18.13 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | 6.725 | 51.84 |
| EBITDA 1 | - | -66.43 | -65.82 | -73.5 |
| EBIT 1 | - | -63.8 | -82.03 | -40.64 |
| Operating Margin | - | - | -1,219.72% | -78.39% |
| Earnings before Tax (EBT) 1 | - | -48.14 | -76.89 | -39.89 |
| Net income 1 | -69.97 | -52 | -66.27 | -53.81 |
| Net margin | - | - | -985.37% | -103.79% |
| EPS 2 | -7.220 | -2.800 | -2.398 | -1.906 |
| Free Cash Flow 1 | - | -42 | -63 | -31 |
| FCF margin | - | - | -936.73% | -59.8% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Announcement Date | 22/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | -16.08 | -16.13 | -16.4 | -17.91 | - | - |
| EBIT 1 | -16.09 | -15 | -16.11 | -16.59 | -15 | -19 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -16.65 | -11 | -11.03 | -9.456 | -13.81 | -17.9 |
| Net income 1 | -16.65 | -12.07 | -12.04 | -11.21 | -13.81 | -17.9 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -3.530 | -0.4737 | -0.4592 | -0.4278 | -0.5350 | -0.7550 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 08/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -42 | -63 | -31 |
| ROE (net income / shareholders' equity) | - | -22.6% | -11% | -0.51% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.02 | 0.02 | - |
| Capex / Sales | - | - | 0.24% | - |
| Announcement Date | 22/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.13
USD
Average target price
35.6
USD
Spread / Average Target
+96.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 463M | |
| +16.73% | 123B | |
| +21.13% | 115B | |
| +21.14% | 25.85B | |
| -17.94% | 20.9B | |
| -16.24% | 16.52B | |
| -11.76% | 16.77B | |
| -44.45% | 15.56B | |
| +69.92% | 15.49B | |
| +1.41% | 13.45B |
- Stock Market
- Equities
- LENZ Stock
- Financials LENZ Therapeutics, Inc.
